Second and third generation ALK specific inhibitors such as ceritinib (LDK378)19, brigatinib (AP26113)20,21, alectinib (CH-5424802)22, and lorlatinib (PF-06463922)23,24 might significantly improve NB treatment options. The gene discussed is ALK; the disease is neuroblastoma.